Marine compounds for the therapeutic treatment of neurological disorders

Bibliography

• NEWMAN D, CRAG G, SNADER K: Natural products as sources of new drugs over the period 1981-2002.1 Nat. Prod. (2003) 66:1022–1037.
   PubMed Web of Science ®Google Scholar
• BREWERS: The relationship between natural products and synthetic chemistry in the discovery process. Chem. Soc. Spec. Pub. (2000) 257:59–65.
   Google Scholar
• PERRY EK, PICKERING AT, WANG WW, HOUGHTON PJ, PERRY NS: Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. j Pharm. PharmacoL (1999) 51:527–534.
   PubMed Web of Science ®Google Scholar
• ROBERSON M, HARRELL L:Cholinergic activity and amyloid precursor protein metabolism. Brain Res. Rev. (1997) 25:50–69.
   PubMed Web of Science ®Google Scholar
• ZAROTSKY V, SRAMEK J, CUTLER N:Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. (2003) 60:446–452.
   PubMed Web of Science ®Google Scholar
• THOMSEN T, KEWITZ H: Selective inhibition of human acetylcholinesterase by galantamine in vitro and in vivo. Life Sci. (1990) 46:1553–1558.
   PubMed Web of Science ®Google Scholar
• RINEHART KL: Antitumor compounds from tunicates. Med. Res. Rev. (2000) 20:1–27.
   PubMed Web of Science ®Google Scholar
• KERR RG, KERR SS: Marine natural products as therapeutic agents. Expert Opin. Ther. Patents (1999) 9:1207–1222.
   Web of Science ®Google Scholar
• FRENZ JI,, KOHL AC, KERR RG: Marine natural products as therapeutic agents: part 2. Expert Opin. Ther. Patents (2004) 14:17–33.
   Web of Science ®Google Scholar
• LEIFER BP: Early diagnosis of Alzheimer's disease: clinical and economic benefits. J. Am. Geriatr. Soc. (2003) 51:281–288.
   PubMed Web of Science ®Google Scholar
• BAYER T, WIRTHS 0, MAJTENYI K et al.: Key factors in Alzheimer's disease: 0-amyloid precursor protein processing metabolism and intraneuronal transport. Brain PathoL (2001) 11:1–11.
   Google Scholar
• IQBAL K, ALONSO AD, GONDAL JA et al.: Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J. Neural Transm. Suppl. (2000) 59:213–222.
   PubMedGoogle Scholar
• TERRY RD: Cell death or synaptic loss in Alzheimer's disease. J. NeuropathoL Exp. NeuroL (2000) 59:1118–1119.
   PubMed Web of Science ®Google Scholar
• LANE R, KIVIPELTO M, GREIG NH: Acetylcholinesterase and its inhibition in Alzheimer's disease. Clin. NeuropharmacoL (2004) 27:141–149.
   PubMed Web of Science ®Google Scholar
• KURZ A: The therapeutic potential of tacrine. J. Neural Transm. SuppL (1998) 54:295–299.
   PubMedGoogle Scholar
• SUGIMOTO H: Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. (2001) 1:63–73.
   PubMed Web of Science ®Google Scholar
• JANN MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy (2000) 20:1–12.
   PubMedGoogle Scholar
• STEWART N, ABRAMSON, ZORAN R et al.: Onchidal: a naturally occurring irreversible inhibitor of AChE with a novel mechanism of action. Mol. Pharm. (1989) 36:349–354.
   Google Scholar
• TURK T, MACEK P, SUPUT D: Inhibition of acetylcholinesterase by a pseudozoanthoxanthin-like compound isolated from the zoanthid Parazoanthus axinellae. Toxicon (1995) 3:133–142.
   Google Scholar
• KRISTINA S, GRACIANO G, INES M et al.: Characterization of anticholinesterase-active-3-alkylpyridinium polymers from the marine sponge Reniera sarai in aquous solutions. J. Nat. Prod (1997) 60:991–996.
   PubMedGoogle Scholar
• SEPCIC K, BATISTA U, VACELET J, MACEK P, TURK T: Biological activities of aqueous extracts from marine sponges and cytotoxic effects of 3-alkylpyridinium polymers from Reniera sarai. Comp. Biochem. PhysioL (1997) 117C:47–53.
   Google Scholar
• MANCINI I, ADRIANA S, GRAZIANO G et al.: Synthesis and biological activity of linear oligomers related to polymeric alkylpyridinium metabolites from the Mediterranean sponge Raniera sarai. Org-. BiomoL Chem. (2004) 2:1368–1375.
   PubMed Web of Science ®Google Scholar
• REVAH F, BERTRAND D, GALZI JL et al.: Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature (1991) 353):846–9.
   PubMedGoogle Scholar
• WHELEER JW, OLUBAJO 0, STROM CB et al: Anabaseine: venom alkaloid of Aphaenogaster ants. Science (1981) 211:1051–1052.
   PubMedGoogle Scholar
• DE FIEBRE CM, MEYER EM, HENRY JC, MURASKIN SI, KEM WR, PAPKE RL: Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic a7/1251-a-bungarotoxin receptor subtypes. Mol. Pharmacol. (1995) 47:164–171.
   PubMed Web of Science ®Google Scholar
• WANG HY LEE DH, DAVIS CB, SHANK RP: Amyloid peptide A0(1-42) binds selectively and with picomolar affinity to a7 nicotinic acetylcholine receptors. Neurochem . (2000) 75:1155–1161.
   PubMedGoogle Scholar
• BRION JP, ANDERTON BH, AUTHELET M et al.: Neurofibrillary tangles and tau phosphorylation. Biochem. Soc. Symp. (2001) 67:81–88
   Google Scholar
• GARCIA ML, CLEVELAND DW: Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. (2001) 13:41–48.
   PubMed Web of Science ®Google Scholar
• MEIJER L, THUNNISSEN AM, WHITE AW et al.: Inhibition of cyclin-dependent kinases, GSK-30 and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. (2000) 7:51–63.
   PubMed Web of Science ®Google Scholar
• WAN Y, CHO Y, MEIJER L et cll.: Synthesis and target identification of hymenialdisine analogs. Chem. Biol. (2004) 11:247–259.
   Google Scholar
• MEIJER L, SKALTSOUNIS A, MAGIATIS P et al.: GSK3-selective inhibitors derived from tyian purple indirubins. Chem. Biol. (2003) 10:1255–1266.
   PubMed Web of Science ®Google Scholar
• GOMPEL M, LEOST M, MEIJER L et al.: Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum. Bioorg-. Med. Chem. Lett. (2004) 14(7):1703–1707.
   PubMedGoogle Scholar
• LAHIRI DK, GE YW, FARLOW MR: Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin. Ann. IVY Acad. Sci. (2000) 903:387–393.
   PubMed Web of Science ®Google Scholar
• CHRISTEN Y: Oxidative stress and Alzheimer's disease. Am. J. Clin. Num (2000) 71:621S–629S.
   Google Scholar
• PRATICO D, DELANTY N: Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. (2000) 109:577–585.
   PubMed Web of Science ®Google Scholar
• SAYRE LM, SMITH MA, PERRY G: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. (2001) 8;:721–738.
   PubMed Web of Science ®Google Scholar
• COLTON CA, CHERNYSHEV ON, GILBERT DL, VITEK MP: Microglial contribution to oxidative stress in Alzheimer's disease. Ann. NY Acad. Sci. (2000) 899:292–307.
   PubMed Web of Science ®Google Scholar
• FLOYD RA: Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic. Biol. Med. (1999) 26:1346–1355.
   PubMed Web of Science ®Google Scholar
• DE LA TORRE JC, STEFANO GB: Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res. Rev. (2000) 34:119–136.
   PubMedGoogle Scholar
• HENSLEY K, ROBINSON KA, GABBITA SP, SALSMAN S, FLOYD RA: Reactive oxygen species, cell signalling, and cell injury. Free Radic. Biol. Med. (2000) 28:1456–1462.
   PubMed Web of Science ®Google Scholar
• ANDERSON I. ADINOLFI C. DOCTROW S et aL: Oxidative signalling and inflammatory pathways in Alzheimer's disease. Biochem . Soc. Symp. (2001) 67:141–149.
   Google Scholar
• PRATICO D, TROJANOWSKI JQ: Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobia Aging (2000) 21:441–445.
   PubMed Web of Science ®Google Scholar
• GRANT MA, MORELLI XJ, RIGBY AC: Conotoxins and structural biology: a prospective paradigm for drug discovery. Curr. Protein Pept. Sci. (2004) 5:235–248.
   PubMed Web of Science ®Google Scholar
• HEADING CE: Conus toxins: targets and properties. IDrugs. (2004) 7:1011–1016.
   PubMedGoogle Scholar
• LIVETT B, GAYLER K, KHALIL Z: Drugs from the sea: conopeptides as potencial therapeutics. Curr. Med. Chem. (2004) 11:1715–1723.
   PubMed Web of Science ®Google Scholar